文献速递眼底病与葡萄膜炎

湿性年龄相关性黄斑变性患者接受抗血管内皮生长因子治疗的体验及抑郁与焦虑的临床水平

Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration.
PubMed 文献 · Am J Ophthalmol · 2017-03-14

该观察性横断面混合方法研究纳入300例接受抗血管内皮生长因子(抗VEGF)治疗的湿性年龄相关性黄斑变性(wAMD)患者及100例照护者,通过结构化调查和标准化问卷评估治疗体验及抑郁、焦虑、创伤后应激水平。56%患者报告与治疗相关的焦虑,17%和12%分别达到焦虑和抑郁的临床水平;接受≤3次注射的患者抑郁水平显著高于接受4-12次(ANOVA P=0.027)和>12次(ANOVA P=0.001)的患者。

要点

  • 56%的wAMD患者报告与抗VEGF治疗相关的焦虑,主要源于担心失明和治疗效果而非疼痛。
  • 17%患者达到焦虑临床水平,12%达到抑郁临床水平。
  • 接受≤3次注射的患者抑郁水平显著高于接受4-12次(P=0.027)和>12次(P=0.001)的患者,焦虑无此差异。

核心结论

  • 抗VEGF治疗通常伴随与治疗相关的一定焦虑,无论注射次数多少。
  • 抑郁的临床水平似乎在抗VEGF治疗早期阶段更常见。

研究设计与样本

  • 观察性横断面混合方法研究,纳入300例接受抗VEGF治疗的wAMD患者和100例患者照护者。

主要发现

  • 定性数据显示56%患者(n=132)报告与抗VEGF治疗相关的焦虑,主要来源为害怕因玻璃体腔注射失明和对治疗效果的担忧,而非疼痛。
  • 标准化问卷显示17%患者(n=52)达到焦虑临床水平,12%(n=36)达到抑郁临床水平。
  • 接受≤3次注射的患者抑郁水平显著高于接受4-12次注射的患者(方差分析P=0.027),也显著高于接受>12次注射的患者(方差分析P=0.001);焦虑水平无显著差异。

临床怎么用

  • 作者建议采取策略改善患者治疗体验并减少疾病负担。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate detailed patient experiences specific to receiving vascular endothelial growth factor inhibitors (anti-VEGF) for wet age-related macular degeneration (wAMD), and to acquire a snapshot of the frequency of clinically significant levels of depression, anxiety, and posttraumatic stress among patients and levels of burden in patients' carers. DESIGN: Observational cross-sectional mixed-methods study. METHODS: Three hundred patients with wAMD receiving anti-VEGF treatment and 100 patient carers were recruited. Qualitative data on patients' experience of treatment were collected using a structured survey. Standardized validated questionnaires were used to quantify clinically significant levels of anxiety, depression, and posttraumatic stress, as well as cognitive function and carers' burden. RESULTS: Qualitative data showed that 56% of patients (n = 132) reported anxiety related to anti-VEGF treatment. The main sources of anxiety were fear of going blind owing to intravitreal injections and concerns about treatment effectiveness, rather than around pain. From validated questionnaires, 17% of patients (n = 52) showed clinical levels of anxiety and 12% (n = 36) showed clinical levels of depression. Depression levels, but not anxiety, were significantly higher in patients who received up to 3 injections compared with patients who received from 4 to 12 injections (analysis of variance [ANOVA] P = .027) and compared with patients who received more than 12 injections (ANOVA P = .001). CONCLUSIONS: Anti-VEGF treatment is often experienced with some anxiety related to treatment, regardless of the number of injections received. Clinical levels of depression seem to be more frequent in patients at early stages of anti-VEGF treatment. Strategies to improve patient experience of treatment and minimize morbidity are suggested.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Senra H, Balaskas K, Mahmoodi N, et al. Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration. Am J Ophthalmol. 2017. PMID: 28302534. doi:10.1016/j.ajo.2017.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。